✦ LIBER ✦

A Review of Cost-Effectiveness Evaluations as Part of National HTA Assessments of Biologic Dmards in the Treatment of Rheumatoid Arthritis

✍ Scribed by Iannazzo, S.; De Francesco, M.; Gomez-Ulloa, D.; Benucci, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PAR9 A SYSTEMATIC REVIEW OF COST-EFFECTI

✍ L Richard; M Brown 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

PAR18 PATIENT COMPLIANCE IN THE TREATMEN

✍ E Schmidt; A Kielhorn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PMS35 COST-EFFECTIVENESS OF BIOLOGIC THE

✍ Emery, P; Taylor, P; Isaacs, JD; Drost, P; Dupont, D; Beresniak, A 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PMS50 Cost-Effectiveness of Biologic Age

✍ C. Valle-Mercado; M.F. Cubides; M. Parra-Torrado; D. Rosselli 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFL

✍ F Carlos-Rivera; A Aguirre-Granados; SOMC Manterola 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Cost-effectiveness modeling of abatacept

✍ Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 183 KB